Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
Table 1
Demographics and baseline clinical characteristics of patients with OAB dry and wet from the EMPOWUR trial.
Characteristic
Dry population†
Wet population‡
Overall population (FAS§)
Placebo (N = 115)
Vibegron (N = 123)
Tolterodine (N = 98)
Placebo (N = 405)
Vibegron (N = 403)
Tolterodine (N = 319)
Placebo (N = 520)
Vibegron (N = 526)
Tolterodine (N = 417)
Mean (SD) age, y
59.5 (14.6)
59.4 (14.0)
60.7 (12.4)
60.0 (13.0)
61.2 (13.1)
59.5 (13.4)
59.9 (13.3)
60.8 (13.3)
59.8 (13.2)
≥65, n (%)
52 (45.2)
50 (40.7)
38 (38.8)
168 (41.5)
192 (47.6)
128 (40.1)
220 (42.3)
242 (46.0)
166 (39.8)
≥75, n (%)
13 (11.3)
16 (13.0)
11 (11.2)
44 (10.9)
59 (14.6)
36 (11.3)
57 (11.0)
75 (14.3)
47 (11.3)
Gender, n (%)
Women
81 (70.4)
88 (71.5)
68 (69.4)
364 (89.9)
361 (89.6)
284 (89.0)
445 (85.6)
449 (85.4)
352 (84.4)
Men
34 (29.6)
35 (28.5)
30 (30.6)
41 (10.1)
42 (10.4)
35 (11.0)
75 (14.4)
77 (14.6)
65 (15.6)
Race, n (%)
White
81 (70.4)
100 (81.3)
63 (64.3)
325 (80.2)
322 (79.9)
254 (79.6)
406 (78.1)
422 (80.2)
317 (76.0)
Black or African American
20 (17.4)
18 (14.6)
21 (21.4)
59 (14.6)
56 (13.9)
48 (15.0)
79 (15.2)
74 (14.1)
69 (16.5)
Asian
12 (10.4)
3 (2.4)
12 (12.2)
17 (4.2)
24 (6.0)
14 (4.4)
29 (5.6)
27 (5.1)
26 (6.2)
Others
2 (1.7)
2 (1.6)
2 (2.0)
4 (1.0)
1 (0.2)
3 (0.9)
6 (1.2)
3 (0.6)
5 (1.2)
Region, n (%)
US
114 (99.1)
123 (100.0)
96 (98.0)
349 (86.2)
349 (86.6)
280 (87.8)
463 (89.0)
472 (89.7)
376 (90.2)
Non-US
1 (0.9)
0
2 (2.0)
56 (13.8)
54 (13.4)
39 (12.2)
57 (11.0)
54 (10.3)
41 (9.8)
Mean (SD) urgency episodes per day
8.6 (5.0)
8.6 (4.4)
8.4 (3.9)
8.0 (4.6)
8.0 (4.4)
7.8 (3.9)
8.1 (4.7)
8.1 (4.4)
7.9 (3.9)
Mean (SD) micturitions per day
11.9 (3.8)
11.3 (3.5)
11.6 (3.0)
11.7 (4.1)
11.3 (3.4)
11.5 (3.2)
11.8 (4.0)
11.3 (3.4)
11.5 (3.2)
FAS, full analysis set; OAB, overactive bladder. †All randomized patients with OAB dry at study entry who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline micturition measurement. ‡All randomized patients with OAB wet at study entry who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline micturition measurement. §All randomized patients who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline micturition measurement.
